Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2022
02 nov. 2022 08h00 HE
|
Morphic Therapeutic
Completed enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis ahead of schedule EMERALD-2 phase 2b global randomized study of MORF-057 to begin fourth quarter ...
Morphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022
25 oct. 2022 16h05 HE
|
Morphic Therapeutic
Saturating receptor occupancy at 100 and 200 mg BID doses Statistically significant effects on key lymphocyte subsets WALTHAM, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq:...
Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections
24 oct. 2022 08h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022
10 oct. 2022 08h00 HE
|
Morphic Therapeutic
200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations Lymphocyte changes consistent with approved α4β7 inhibitor ...
Morphic Congratulates Timothy A. Springer, PhD as 2022 Albert Lasker Basic Medical Research Award Honoree
28 sept. 2022 12h00 HE
|
Morphic Therapeutic
Recognized for pioneering work in field of integrin receptor biology, leading to new treatments for multiple autoimmune disorders Founder, Director, and Scientific Advisory Board member of Morphic...
Morphic Celebrates Foundational Integrin Research Published in Cell
21 sept. 2022 07h00 HE
|
Morphic Therapeutic
Paper describes key insight into integrin conformation, overcoming critical drug development challenge Company lauds Tim Springer, PhD, scientific founder of Morphic and Fu-Yang “Albert” Lin, PhD,...
Morphic Announces Participation in 2022 Wells Fargo Healthcare Conference
01 sept. 2022 08h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2022
03 août 2022 08h00 HE
|
Morphic Therapeutic
Continued enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis Announced key appointments and advancements in leadership team Ended second quarter 2022 with $397.6...
Morphic to Present at 2022 Jefferies Global Healthcare Conference
09 juin 2022 09h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs
18 mai 2022 07h30 HE
|
Morphic Therapeutic
WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...